Lifeline Systems Newswire

Lifeline Systems Newswire

Comprehensive Real-Time News Feed for Lifeline Systems.

Results 1 - 20 of 48 in Lifeline Systems

  1. aTyr Pharma Appoints As Senior Vice President, Product Programs And PlanningRead the original story

    15 hrs ago | BioSpace

    Mr. Matsuoka will drive the strategic elements of the company's development-stage programs, most notably development of the company's lead candidate, Resolaris, as the company seeks to advance meaningful medicines that promote tissue homeostasis for patients with various severe and rare diseases through the clinic. "As we continue to advance Resolaris in clinical development, we are excited to welcome Mr. Matsuoka to our team," said , PhD, Chief Executive Officer of aTyr Pharma.

    Comment?

  2. aTyr Pharma to Present at Upcoming May Investor ConferencesRead the original story

    Friday Apr 29 | Freshnews

    SAN DIEGO, April 29, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation in two upcoming investor conferences.

    Comment?

  3. Senior leader takes helm in BillericaRead the original story w/Photo

    Sunday Apr 17 | Lowell Sun

    ... led business development for the Visiting Nurse Association (VNA) of Boston, and held key roles at Lifeline Systems (now Philips Lifeline). "Donna did a superb job, so I'm studying all that's been done, and I want to build on that," Bushnell said. ...

    Comment?

  4. Senior leader takes helm in BillericaRead the original story w/Photo

    Sunday Apr 17 | Lowell Sun

    ... led business development for the Visiting Nurse Association (VNA) of Boston, and held key roles at Lifeline Systems (now Philips Lifeline). "Donna did a superb job, so I'm studying all that's been done, and I want to build on that," Bushnell said. ...

    Comment?

  5. Paul Schimmel Buys 66,219 Shares of aTyr Pharma (LIFE) StockRead the original story w/Photo

    Friday Apr 15 | AmericanBankingNews.com

    The stock was purchased at an average price of $4.18 per share, with a total value of $276,795.42. Following the purchase, the director now owns 53,012 shares in the company, valued at $221,590.16.

    Comment?

  6. Insider Buying: aTyr Pharma (LIFE) Director Buys 85,000 Shares of StockRead the original story w/Photo

    Monday Apr 11 | Daily Political

    The shares were purchased at an average cost of $3.22 per share, for a total transaction of $273,700.00. Following the completion of the transaction, the director now owns 187,572 shares of the company's stock, valued at $603,981.84.

    Comment?

  7. aTyr Pharma (LIFE) Stock Price Up 10.3% After Insider Buying ActivityRead the original story w/Photo

    Monday Apr 11 | AmericanBankingNews.com

    The stock traded as high as $3.61 and last traded at $3.53, with a volume of 1,518,518 shares changing hands. The stock had previously closed at $3.20.

    Comment?

  8. aTyr Pharma (LIFE) Director Paul Schimmel Purchases 40,000 SharesRead the original story w/Photo

    Friday Apr 8 | AmericanBankingNews.com

    The stock was acquired at an average price of $3.19 per share, for a total transaction of $127,600.00. Following the completion of the transaction, the director now owns 102,572 shares in the company, valued at approximately $327,204.68.

    Comment?

  9. Paul Schimmel Acquires 25,000 Shares of aTyr Pharma (LIFE) StockRead the original story w/Photo

    Wednesday Apr 6 | AmericanBankingNews.com

    The shares were purchased at an average price of $3.52 per share, with a total value of $88,000.00. Following the transaction, the director now owns 37,572 shares in the company, valued at approximately $132,253.44.

    Comment?

  10. FY2016 EPS Estimates for aTyr Pharma Decreased by AnalystRead the original story w/Photo

    Apr 4, 2016 | AmericanBankingNews.com

    Research analysts at William Blair decreased their FY2016 earnings per share estimates for shares of aTyr Pharma in a report issued on Thursday, Zacks Investment Research reports. William Blair analyst Y. Xu now forecasts that the firm will post earnings per share of for the year, down from their previous forecast of .

    Comment?

  11. aTyr Pharma (LIFE) Stock Rating Lowered by William BlairRead the original story w/Photo

    Mar 31, 2016 | AmericanBankingNews.com

    LIFE has been the subject of several other research reports. Citigroup Inc. initiated coverage on shares of aTyr Pharma in a report on Wednesday, December 16th.

    Comment?

  12. aTyr Pharma Announces Encouraging Phase 1b/2 Results For Resolaris In Its First Rare Myopathy TrialRead the original story

    Mar 30, 2016 | BioSpace

    The Company is developing Resolaris, a potential first-in-class protein therapeutic, for the treatment of rare myopathies with an immune component . The Phase 1b/2 study was designed to evaluate the safety, tolerability, immunogenicity and pharmacokinetic profile of Resolaris in adult FSHD patients, the Company's first treated RMIC population.

    Comment?

  13. aTyr Pharma Announces Fourth Quarter 2015 Operating ResultsRead the original story

    Mar 30, 2016 | BioSpace

    The Company expects general and administrative expenses to increase substantially to support the continued development of its product candidates and the costs associated with operating as a public company, which include supporting regulatory and listing requirements, insurance and investor relations. These increases will also include the cost of additional personnel and fees to outside consultants, among other expenses.

    Comment?

  14. aTyr Pharma Appoints As Chief Medical OfficerRead the original story

    Mar 30, 2016 | BioSpace

    Dr. Shukla will lead aTyr's clinical efforts to advance its Physiocrine biology therapeutic intervention points and strategically develop meaningful medicines that promote tissue homeostasis for patients with various severe and rare diseases. "As we continue to advance Physiocrine-based product candidates in clinical development, we are excited to welcome Dr. Shukla to our team, and to have him join our efforts of advancing innovative therapeutics, based on new biology, to patients in need," said , PhD, Chief Executive Officer of aTyr Pharma.

    Comment?

  15. aTyr Pharma (LIFE) Short Interest UpdateRead the original story w/Photo

    Feb 14, 2016 | AmericanBankingNews.com

    As of January 29th, there was short interest totalling 693,717 shares, a decline of 21.6% from the January 15th total of 885,153 shares, Marketbeat reports. Currently, 5.2% of the shares of the company are short sold.

    Comment?

  16. aTyr Pharma (LIFE) Receives Overweight Rating from JPMorgan Chase & Co.Read the original story w/Photo

    Jan 14, 2016 | AmericanBankingNews.com

    's stock had its "overweight" rating reissued by equities researchers at JPMorgan Chase & Co. in a research note issued on Thursday, MarketBeat.Com reports.

    Comment?

  17. aTyr Pharma Provides Corporate Update And Outlook For 2016Read the original story

    Jan 10, 2016 | BioSpace

    "We are pleased by our pipeline progress to date and look forward to further progress in 2016. We expect data from our first Resolaris trial in adult facioscapulohumeral muscular dystrophy patients at approximately the end of the first quarter that will further inform our clinical strategy moving forward for Resolaris in both muscle and lung indications," said , Ph.D., CEO of aTyr Pharma.

    Comment?

  18. aTyr Pharma Appoints As Chief Business OfficerRead the original story

    Jan 6, 2016 | BioSpace

    Dr. Ravindran will lead aTyr's corporate development and strategy efforts, including the planning and execution of strategic growth initiatives as the company advances its mission to make meaningful medicines for patients with serious diseases. "As we continue to realize the promise of Physiocrines, harnessing the body's natural immune processes to develop new treatments for rare diseases, we are thrilled with the addition of Dr. Ravindran to our team," said , Ph.D., CEO of aTyr Pharma.

    Comment?

  19. HFF Arranges $29M for Hilton Garden Inn CarlsbadRead the original story w/Photo

    Dec 21, 2015 | GlobeSt.com

    NEW event in SoCal! Meet the people leading the sector at RealShare Industrial West . The Westin Long Beach, January 19-20.

    Comment?

  20. aTyr Pharma (LIFE) Receives New Coverage from Analysts at Citigroup Inc.Read the original story w/Photo

    Dec 16, 2015 | AmericanBankingNews.com

    The brokerage set a "neutral" rating on the stock. LIFE has been the topic of a number of other research reports.

    Comment?